Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Camrelizumab + SHR7390 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Camrelizumab | SHR-1210|INCSHR-1210 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Camrelizumab (SHR-1210) is an antibody that targets PD-1 (PDCD1) and inhibits binding of PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in activation of anti-tumor immune response and decreased tumor growth (PMID: 29358502, PMID: 32623573, PMID: 32581041). | |
SHR7390 | SHR 7390|SHR-7390 | MEK1 Inhibitor 26 MEK2 Inhibitor 24 | SHR7390 inhibits MEK1 and MEK2, which potentially decreases tumor growth (PMID: 36398872). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|